Most people with depression are likely to receive Antidepressants as a first step when consulting their doctor for support. Although this isn’t ideal, it is often the only alternative available because lengthy waiting periods combined with a lack of funding means that other forms of treatments like cognitive therapy can not be available immediately. Check TMS Clinic near me.
While antidepressants are effective for many, any relief they give comes with the price of suffering some unpleasant side effects, including nausea , dizziness, sleep disturbances, headaches, loss of libido, agitation, and erectile dysfunction in men. Another issue is that in some people antidepressants will have no effect whatsoever on the symptoms of depression. No one really knows why this is the case, and projecting which people will gain and who won’t.
Now, a recent study has highlighted an groundbreaking intervention that is rapidly gaining attention as a potential rehabilitation treatment for severe depression in people who either couldn’t take antidepressants or felt the antidepressant medications didn’t function.
Transcranial magnetic stimulation, or TMS as it is known, is a treatment that involves magnets placed on the head to send magnetic pulses to the parts of the brain that regulate mood.
Neurostar Inc. is the company that developed Neurostar TMS machine that apparently carries very few side effects, if any. After treatment the most common is a mild headache.
In a pilot study performed by Neurostar, the researchers treated half of the TMS patients for a six-week duration, and the other half were monitored weekly. We found that 61.2 percent of those treated with TMS had undergone a reversal of symptoms of depression during the six-week period, and after three months the figure was 62.5 percent compared to 43.8 percent of those who did not undergo TMS therapy.
“This pilot study supports the idea that maintenance TMS can be helpful in avoiding major depression recurrence and is an significant step in understanding what the optimal treatment criteria should be,” Dr. Scott Aaronson, Director of Clinical Research Services and Associate Medical Director at Sheppard Pratt, said in a statement.